Survival outcomes for patients with invasive lobular cancer by MammaPrint: Results from the MINDACT phase III trial
Authors:
- 22 January 2025
- journal article
- Published by Elsevier in European Journal of Cancer
- Vol. 217, 115222
Abstract
No abstract availableKeywords
Funding Information
- Breast Cancer Research Foundation
This publication has 37 references indexed in Scilit:
- The 70-gene signature test as a prognostic and predictive biomarker in patients with invasive lobular breast cancerBreast Cancer Research and Treatment, 2021
- Differential impact of prognostic parameters in hormone receptor–positive lobular breast cancerCancer, 2020
- The impact of chemotherapy sequence on survival in node‐positive invasive lobular carcinomaJournal of Surgical Oncology, 2019
- Adjuvant chemotherapy in lobular carcinoma of the breast: a clinicopathological score identifies high-risk patient with survival benefitBreast Cancer Research and Treatment, 2019
- Impact of the 21-gene recurrence score on outcome in patients with invasive lobular carcinoma of the breastBreast Cancer Research and Treatment, 2017
- Relative effectiveness of adjuvant chemotherapy for invasive lobular compared with invasive ductal carcinoma of the breastCancer, 2017
- Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancerBreast Cancer Research and Treatment, 2012
- Invasive lobular breast cancer: subtypes and outcomeBreast Cancer Research and Treatment, 2012
- The molecular underpinning of lobular histological growth pattern: a genome‐wide transcriptomic analysis of invasive lobular carcinomas and grade‐ and molecular subtype‐matched invasive ductal carcinomas of no special typeThe Journal of Pathology, 2009
- Trends in Incidence Rates of Invasive Lobular and Ductal Breast CarcinomaJAMA, 2003